

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Rymo raises Rs 10 Cr seed funding led by IAN Angel Fund

21 March 2026 | News

Fresh capital will be used to accelerate product innovation, expand manufacturing capabilities



IAN Group, the country's single largest early-stage investment platform, has invested in Rymo Technologies, a robotic neuro-rehabilitation startup in its seed funding round of over Rs 10 crore through its evergreen fund, IAN Angel Fund, with participation from other angel investors.

The fresh capital will be used to accelerate product innovation, expand manufacturing capabilities, and strengthen the company's presence across India while scaling into international markets, including ASEAN and the Middle East.

Founded by Chirag Shah (CEO) and Abhishek Rai (CTO), Mumbai-based Rymo Technologies is working to address a structural gap in neuro-rehabilitation. While the incidence of stroke and neurological disorders continues to rise globally, access to advanced rehabilitation remains limited due to a shortage of trained therapists and the high cost of robotic rehabilitation systems. As a result patients in Tier 1 and 2 cities, and smaller hospitals often lack access to advanced therapy solutions.

The company has already demonstrated strong traction across the healthcare ecosystem, with more than 452 device installations and 354 clinical customers, including leading institutions such as AIIMS, Apollo Hospitals, and Manipal Hospitals. Rymo's systems have supported over 7,500 patients, delivering more than 15,000 therapy hours, with studies indicating up to 25 percent faster recovery outcomes.

Rymo's approach focuses on bringing robotic and AI-assisted rehabilitation technology to mid-sized hospitals and physiotherapy clinics at an accessible price point, enabling healthcare providers beyond large metropolitan hospitals to deliver advanced rehabilitation services.

The company has also made progress on regulatory and international expansion fronts. Rymo has received US FDA classification as a Class II medical device and has signed a distribution partnership with Fourier Rehab to expand into ASEAN markets.